Insmed’s once-daily TPIP prodrug shows sustained lung vasodilation in PAH and PH-ILD, improving walk distance, PALM outcomes, ...

ARLINGTON, Va. , Oct. 9, 2026 /PRNewswire/ -- The Board of Directors of The AES Corporation (NYSE: AES) declared a quarterly common stock dividend of $0.17595 per share payable on November 13, 2026 to ...

Hello. I am Yoshiyuki Ose, Representative Director and CEO of Patent Integration, Inc., and a patent attorney."I want to use ...

PRNewswire/ -- (Muna), a clinical-stage biotechnology company developing innovative treatments for neurodegenerative diseases ...

In this phase3 trial, researchers explored whether a chemotherapy-free strategy was superior to a tyrosine kinase inhibitor plus chemotherapy in Ph-positive ALL.

(p=0.0190). The therapy represents a new non-immune suppressive treatment modality, designed to achieve delivery to the distal colon with a novel liquid to gel delivery system, and a neutral pH. The ...

REC-1245 (RBM39 degrader) Phase 1 Data Update: Encouraging monotherapy activity with 2 confirmed partial responses in endometrial cancer, 1 unconfirmed response in liver cancer, and a 91.7% disease ...

A Phase 1b cohort in eosinophilic esophagitis (EoE) is enrolling 50 patients with top-line data anticipated in Q3 2027. Additionally, we are also on track to initiate Phase 2 development in vitiligo ...

An MF59-adjuvanted, higher-dose influenza vaccine improves immune responses in older adults compared with standard egg-based options.

About two-thirds of eligible patients needed no retreatment after week 16; most who did needed one more injection. FDA ...

Error handling ran through much of this week’s news. Pasqal won French backing to lead a fault-tolerance programme, D-Wave opened a simulator for testing error-aware code, and Classiq released a tool ...

If approved, TALVEY® plus daratumumab will be the only GPRC5D-targeting bispecific antibody combination therapy for relapsed or refractory multiple myeloma as early as second lineCHMP recommendation ...